

(43) International Publication Date
16 September 2010 (16.09.2010)(10) International Publication Number
WO 2010/104194 A1

(51) International Patent Classification:

C07D 307/79 (2006.01) **C07D 413/04** (2006.01)
C07D 307/80 (2006.01) **C07D 413/12** (2006.01)
C07D 307/81 (2006.01) **C07D 417/12** (2006.01)
C07D 405/04 (2006.01) **C07D 493/10** (2006.01)
C07D 405/12 (2006.01) **A61K 31/496** (2006.01)
C07D 405/14 (2006.01) **A61K 31/5377** (2006.01)
C07D 407/04 (2006.01) **A61K 31/551** (2006.01)
C07D 407/12 (2006.01)

(21) International Application Number:

PCT/JP2010/054286

(22) International Filing Date:

9 March 2010 (09.03.2010)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2009-056719 10 March 2009 (10.03.2009) JP

(71) Applicant (for all designated States except US): **TAKE-DA PHARMACEUTICAL COMPANY LIMITED** [JP/JP]; 1-1, Doshomachi 4-chome, Chuo-ku, Osaka-shi, Osaka, 5410045 (JP).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **TSUKAMOTO, Tetsuya** [JP/JP]; c/o TAKEDA PHARMACEUTICAL COMPANY LIMITED, 17-85, Jusohonmachi 2-chome, Yodogawa-ku, Osaka-shi, Osaka, 5328686 (JP). **WAKABAYASHI, Takeshi** [JP/US]; 12B Downing Square,

Guilderland, New York, 12084 (US). **OHRA, Taiichi** [JP/JP]; c/o TAKEDA PHARMACEUTICAL COMPANY LIMITED, 17-85, Jusohonmachi 2-chome, Yodogawa-ku, Osaka-shi, Osaka, 5328686 (JP).


(74) Agents: **KOBAYASHI, Hiroshi** et al.; ABE, IKUBO & KATAYAMA, Fukuoka Bldg. 9th Fl., 8-7, Yaesu 2-chome, Chuo-ku, Tokyo, 1040028 (JP).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: BENZOFURAN DERIVATIVES



(57) Abstract: The present invention provides a compound represented by the following formula (I): wherein: Ring A represents an optionally substituted piperazine ring, an optionally substituted morpholine ring, or an optionally substituted homopiperazine ring; R₁ and R₂ are the same or different from each other, and represent a hydrogen atom or optionally substituted lower alkyl; R₃ and R₄ are the same or different from each other, and represent a hydrogen atom or halogenated or non-halogenated lower alkyl; R₅ to R₇ are the same or different from each other, and represent a hydrogen atom, hydroxy, optionally substituted lower alkyl, optionally substituted lower alkenyl, optionally substituted lower alkoxy, optionally substituted cycloalkyl, optionally substituted aryl, an optionally substituted aromatic heterocyclic ring, optionally substituted amino, or acyl; and represents a single bond or double bond, wherein R₂ and R₃ do not exist when carbon atoms respectively adjacent to R₂ and R₃ form a double bond, and there is no case where all of R₁ to R₇ are hydrogen atoms, and R₁ and R₂ may form a ring together with an adjacent carbon atom; or a salt thereof.

WO 2010/104194 A1



Published:

— *with international search report (Art. 21(3))*